Literature DB >> 11756175

Human T-cell leukemia virus type 2 induces survival and proliferation of CD34(+) TF-1 cells through activation of STAT1 and STAT5 by secretion of interferon-gamma and granulocyte macrophage-colony-stimulating factor.

Chiara Bovolenta1, Elisabetta Pilotti, Massimiliano Mauri, Marco Turci, Paolo Ciancianaini, Paola Fisicaro, Umberto Bertazzoni, Guido Poli, Claudio Casoli.   

Abstract

Human T-cell leukemia-lymphoma virus (HTLV) type-2 can induce the survival and proliferation of CD34(+) TF-1 cells deprived of interleukin (IL)-3. This effect did not require productive infection and occurred when HTLV-2 was produced from T cells (CMo), but not from B cells (BMo), unless the latter virus was complexed with anti-HLA-DR monoclonal antibodies (mAbs). Cellular and molecular mechanisms triggered by HTLV-2 interaction with TF-1 cells were here investigated. Activation of signal transducer and activator of transcription (STAT) 5 protein occurred in TF-1 cells incubated either with IL-3 or with HTLV-2/CMo; in addition the virus, but not IL-3, activated STAT1. The effect of HTLV-2 required several hours, suggesting dependence on the induction of cellular factors. By screening a panel of secreted factors, granulocyte macrophage-colony-stimulating factor (GM-CSF), interferon (IFN)-gamma, and stem cell factor (SCF) were found induced by HTLV-2 in TF-1 cells. Of note is the fact that these molecules induce a variety of biologic effects through the activation of STAT proteins, including STAT1 and STAT5. Neutralization experiments indicated that GM-CSF and IFN-gamma, but not SCF, were responsible for HTLV-2-induced STAT activation, whereas anti-GM-CSF antibodies greatly inhibited TF-1 cell proliferation. Finally, incubation of BMo virus with anti-HLA-DR mAb rescued TF-1 cell survival in the absence of IL-3. Thus, HTLV-2 interaction with CD34(+) precursor cells may lead to the expression of cytokines that, by inducing autocrine activation of STATs, may influence the host's regenerative capacity and immune response to HTLV-2 and to other infectious agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11756175     DOI: 10.1182/blood.v99.1.224

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway.

Authors:  Yi-Hua Qian; Qingli Xiao; Hong Chen; Jan Xu
Journal:  Biochim Biophys Acta       Date:  2009-02-07

2.  Human T-cell leukemia virus type 1 tax oncoprotein suppression of multilineage hematopoiesis of CD34+ cells in vitro.

Authors:  Adam Tripp; Yingxian Liu; Michelle Sieburg; Joanne Montalbano; Stephen Wrzesinski; Gerold Feuer
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 3.  HTLV-1/-2 and HIV-1 co-infections: retroviral interference on host immune status.

Authors:  Elisabetta Pilotti; Maria V Bianchi; Andrea De Maria; Federica Bozzano; Maria G Romanelli; Umberto Bertazzoni; Claudio Casoli
Journal:  Front Microbiol       Date:  2013-12-23       Impact factor: 5.640

4.  A Panel of Eight miRNAs Is Deregulated in HTLV-2 Infected PBMCs and BJABGu Cell Line.

Authors:  Elisabetta Pilotti; Attilio Cannata; Giacomo Magnani; Fabio Bignami; Andrea Corsi; Maria Teresa Valenti; Mariam Shallak; Greta Forlani; Maria Grazia Romanelli
Journal:  Int J Mol Sci       Date:  2022-07-08       Impact factor: 6.208

5.  Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection.

Authors:  Edward L Murphy; Baoguang Wang; Ronald A Sacher; Joy Fridey; James W Smith; Catharie C Nass; Bruce Newman; Helen E Ownby; George Garratty; Shelia T Hutching; George B Schreiber
Journal:  Emerg Infect Dis       Date:  2004-01       Impact factor: 6.883

Review 6.  Genetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV Infections.

Authors:  Tatiane Assone; Arthur Paiva; Luiz Augusto M Fonseca; Jorge Casseb
Journal:  Viruses       Date:  2016-02-03       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.